HSPA4 and neoplasm: Preclinical investigations have demonstrated that JG-231, a hydrophilic derivative of the HSP70 inhibitor MKT-077, effectively suppresses tumor growth in PDAC models harboring the KRASG12C mutation, suggesting a promising therapeutic approach tailored to molecular tumor profiles [65].